BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

Near-complete in vitro TTR stabilization was observed as early as day 28 and through completion of a 30-month study of patients with ATTR-CM. The Food and Drug Administration (FDA) has approved ...

BridgeBio Pharma (BBIO) just delivered quarterly revenue that topped expectations, powered by stronger than anticipated U.S. sales of its cardiomyopathy drug Attruby, and the stock’s reaction shows ...

As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers since FDA approval in November 2024. The third quarter revenue totaled $120.7 million, ...

-Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of ...

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby was designed to mimic a naturally occurring "rescue mutation" of the TTR gene (T119M) ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx(R) Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by ...

- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial ...